MAPT and Alzheimer disease: The AD biomarkers, such as CSF measures of Aβ1-42, t-tau, and p-tau, can assess aged patients’ overall health and diseased condition and the pathogenic processes and pharmacological effects of any therapy (Olsson et al., 2016).